Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00727064 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00727064 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT00727064, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
Interventions
- DRUG Desvenlafaxine Succinate Sustained-Release (DVS SR)
- DRUG Venlafaxine Extended Release (VEN ER)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00727064
The ClinicalTrials.gov registry entry for NCT00727064 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Desvenlafaxine Succinate Sustained-Release (DVS SR) is the first listed.
NCT00727064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00727064 about?
NCT00727064 is a clinical study titled "Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects". The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
What is the current status of trial NCT00727064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2008-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00727064?
The interventions under investigation include: Desvenlafaxine Succinate Sustained-Release (DVS SR) (DRUG), Venlafaxine Extended Release (VEN ER) (DRUG).
Who is sponsoring clinical trial NCT00727064?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.